A Phase 2/3 interventional study of The investigational product specifically targeting P. aeruginosa (DP-QB-PSA-005) and that targeting S. aureus (DP-QB-STA-005), each formed of a mixture of 5 bacteriophages. in Periprosthetic Infection, sponsored by Ottawa Hospital Research Institute. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Ottawa Hospital Research Institute · Phase 2/3, Interventional, and Treatment
Total joint replacement (TJR) has revolutionized care provided for patients suffering from disabling joint pain. Unfortunately, periprosthetic joint infection (PJI) remains a devastating complication and the leading cause of failure after TJR. Current standard treatment for PJI requires multiple surgical revisions of the infected prosthesis in combination with a prolonged course of systemic antibiotic therapy. Debridement Antibiotic and Implant Retention (DAIR) procedure is one of the surgical options that is routinely used to manage PJI, due to its lower risk of morbidity and surgical cost. DAIR is often used for patients who present with an acute PJI or who cannot tolerate a complex implant revision. However, the overall success rate for DAIR is ranging between 60-70%. DAIR failures are often attributed to the residual infection and biofilm burden left behind on the retained implant surface, which cannot be targeted effectively with post-operative systemic antibiotics. Therefore, research has been ongoing to identify non-surgical multidrug resistance (MDR) treatment adjuncts that can synergize the therapeutic effects of antibiotics in PJI care.
Numerous preclinical bone and joint infection models have clearly demonstrated such therapeutic benefits using bacteriophages (phages). Phages target bacterial cells and breakdown biofilm that it forms on the implant surface. Each bacterial strain tends to have a particular phage that is susceptible to that bacterial strain. Due to this phage specificity and the fact that bacteria can still develop resistance against a single phage, the concept of using a phage cocktail (mixture of 2 or more phage candidates) has been the preferred treatment approach for applying phage therapy. Using a phage cocktail provides a broader spectrum of bacterial strain coverage and makes it harder for the bacteria to develop resistance. Published literature has considered phage therapy to be safe for direct administration at the infection site with minimal adverse events provided that the phage preparation administered meets Good Manufacturing Practice (GMP).
The DePHEAT PJI trail, is a prospective, single center, 1:1 non-blinded feasibility randomized controlled trial (RCT) that aims to assess the safety and the effectiveness of the experimental phage therapy cocktails for patients with hip or knee PJI caused by either Staphylococcus (S.) aureus or Pseudomonas (P.) aeruginosa and comparing it to standardized therapy.
The investigator hypothesizes that this pilot RCT will help evaluate the practicality and potential risks associated with adding phage therapy to the conventional standard of care treatment plan. This will initiate the development of a necessary infrastructure for future phage trials and programs that expand our understanding on the benefits of using phage therapy for acute PJI.
Total joint replacement (TJR) has revolutionized care provided for patients suffering from disabling joint pain. Unfortunately, periprosthetic joint infection (PJI) remains a devastating complication and the leading cause of failure after TJR. While the current cost in Canada per hip or knee TJR averages $7k CAD, the cost to treat a PJI complication after a hip or knee TJR is five times that amount. In addition, data collected by national and international joint replacement registries demonstrate that the health and economic burden of PJI is a mounting crisis due to the exponential increase in demand for TJR. Current standard treatment for PJI requires multiple surgical revisions of the infected prosthesis in combination with a prolonged course of systemic antibiotic therapy. This standard treatment approach has a failure rate of 20-30%. Unfortunately, this treatment failure is often associated with high rates of psychological distress, limb amputations and death. Debridement Antibiotic and Implant Retention (DAIR) procedure is one of the surgical options that is routinely used to manage PJI, due to its lower risk of morbidity and surgical cost. DAIR is often used for patients who present with an acute PJI or who cannot tolerate a complex implant revision. However, the overall success rate for DAIR is at the lower end of the spectrum, ranging between 60-70%. DAIR failures are often attributed to the residual infection and biofilm burden left behind on the retained implant surface, which cannot be targeted effectively with post-operative systemic antibiotics. Therefore, research has been ongoing to identify non-surgical multidrug resistance (MDR) treatment adjuncts that can synergize the therapeutic effects of antibiotics in PJI care.
Numerous preclinical bone and joint infection models have clearly demonstrated such therapeutic benefits using bacteriophages (phages). Phages target bacterial cells and breakdown biofilm that it forms on the implant surface. Each bacterial strain tends to have a particular phage that is susceptible to that bacterial strain. Due to this phage specificity and the fact that bacteria can still develop resistance against a single phage, the concept of using a phage cocktail (mixture of 2 or more phage candidates) has been the preferred treatment approach for applying phage therapy. Using a phage cocktail provides a broader spectrum of bacterial strain coverage and makes it harder for the bacteria to develop resistance. Over the past decade, there has been a rise in international interest and effort to translate the antimicrobial therapeutic potential of phages towards this challenging group of patients suffering from bone and joint infections. Published literature has considered phage therapy to be safe for direct administration at the infection site with minimal adverse events provided that the phage preparation administered meets Good Manufacturing Practice (GMP).
The overarching purpose of this trial is to assess the feasibility, safety and effectiveness of phage therapy in patients with hip or knee PJI. The investigators hypothesize that this pilot RCT will help evaluate the practicality and potential risks associated with adding phage therapy to the conventional standard of care treatment plan. This will initiate the development of a necessary infrastructure for future phage trials and programs that expand our understanding on the benefits of using phage therapy for acute PJI.
Ottawa Hospital Research Institute is the lead sponsor of 538 studies on the registry; 100 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients will receive the standard of care for hip and knee periprosthetic joint infection which is DAIR ( Debridement Antibiotic and Implant Retention) and antibiotic according to the bacterial culture.
In addition to the standard of care procedure (DAIR and antibiotics), patients in the experimental arm will receive 3 doses of intra-articular phage therapy. The first dose will be given intra-operatively after the DAIR and then will be done at day 14 and day 21 postoperatively. The second and third intra-articular injections will be done under image guidance.
Biological: The investigational product specifically targeting P. aeruginosa (DP-QB-PSA-005) and that targeting S. aureus (DP-QB-STA-005), each formed of a mixture of 5 bacteriophages.
For participants randomized to the intervention arm will receive a total of 3 local administrations (intra-articular) of the appropriate phage cocktail to the infected joint. The first dose will be administered intraoperatively during the DAIR procedure after closing the joint capsule. The second dose will be administered on post-operative days (POD) 14 and the third dose will be administered POD 21. The second and third doses will be administered by interventional radiology using image guidance (fluoroscopy) as per standard drug administration.
Also known as: Bacteriophage therapy
Incidence of treatment emergent adverse event
focuses on documenting any adverse events (both transient and persistent) or reactions associated with phage therapy. * Monitoring for signs and symptoms of allergic reactions after each phage administration, which could be manifested as fever, rash, flushing, hypotension * Monitoring for any signs and symptoms of emerging new infections * Monitoring for emergence of resistance to phage therapy or to antibiotics
Time frame: up to 12 months
Evaluation of the feasibility of the trial design
To assess the practical aspect of administering phage therapy in a hospital setting. This trial will define the achievability of performing a future larger scale trial. This trial will be evaluating the following: * logistical challenges related to transportation, storage and handling of phage therapy * operational challenges including technical and time feasibility factors * patient recruitment and acceptance to participating in such a trial
Time frame: up to 3 months
Assessment of clinical response effectiveness to phage therapy
Clinical effectiveness would be assessed through * Functional and mobility assessments during the study period using Patient Reported Outcome Measures (PROMS) and clinical examination of participants range of motion compared to the baseline. * The absence of the need for re-interventions and repetitive debridement
Time frame: up to 12 months
Assessment of Microbiological effectiveness of phage therapy
Microbiological effectiveness includes the absence of isolated bacterial culture after phage therapy treatment.
Time frame: up to 12 months
Assessment of biochemical effectiveness of the phage therapy
Monitoring of the serum inflammatory markers compared to the baseline
Time frame: Up to 12 months
Plan to share: No — Information about study participants will be kept confidential and managed according to the requirements of the Health Insurance Portability and Accountability Act (HIPAA) of 1996. All personal health information will be kept confidential, unless release is required by law. Representatives of government regulators such as Health Canada, representatives of The Ottawa Hospital Research Ethics Board (OHSN-REB) as well as the Ottawa Hospital Research Institute may review the original, relevant medical records under the supervision of the QI and the study team for monitoring and auditing purposes
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ottawa Hospital Research Institute